|
|
CCO Gone
Feb 26, 2020 18:25:47 GMT -5
via mobile
mango likes this
Post by sportsrancho on Feb 26, 2020 18:25:47 GMT -5
You don’t get it ..people are not staying on the drug!!... because they aren’t getting the right instructions, the dosing, the handholding that they need ..along with the right protocols that come with off-label instructions. You have to get ahead of the cough. Acknowledge it might be there. Vdex Protocols addressed this. Along with addressing some other issues so you don’t need follow up doses, and actually get the freedom from diabetes that diabetics so deserve! Wake up ..learn to recognize the truth when you hear it!! My God look at the refills ..it’s right in front of your face, the whole time it’s been right in front of your face! LOL...I think you misinterpreted/misunderstood something. We're talking about two diff things. He said it AFREZZA. Not "the right instructions, the dosing, the handholding that they need" etc... Anyways, no where did I ever make a comment about any of what you just said! You're lashing out because you're emotionally upset? Ok, Sorry for that rant🤣..what did you mean by why even bother? |
|
|
|
Post by mango on Feb 26, 2020 18:27:28 GMT -5
LOL...I think you misinterpreted/misunderstood something. We're talking about two diff things. He said it AFREZZA. Not "the right instructions, the dosing, the handholding that they need" etc... Anyways, no where did I ever make a comment about any of what you just said! You're lashing out because you're emotionally upset? Ok, Sorry for that rant🤣..what did you mean by why even bother? Because like brother implied, I thought he meant Afrezza is a terrible/sucky product and no one wants it. Obviously I also misunderstood what he meant as well. Sorry ☹️ |
|
|
|
Post by goyocafe on Feb 26, 2020 18:29:50 GMT -5
I am offended by the salary he makes, regardless of his title. I've never known an HR top position worth that much. Period. This offense is exacerbated by the fact that this is a small company that does not do enough volume of recruiting to make this position worthy of a full time employee. What does he do all day? |
|
|
|
Post by sportsrancho on Feb 26, 2020 18:30:47 GMT -5
You don’t get it ..people are not staying on the drug!!... because they aren’t getting the right instructions, the dosing, the handholding that they need ..along with the right protocols that come with off-label instructions. You have to get ahead of the cough. Acknowledge it might be there. Vdex Protocols addressed this. Along with addressing some other issues so you don’t need follow up doses, and actually get the freedom from diabetes that diabetics so deserve! Wake up ..learn to recognize the truth when you hear it!! My God look at the refills ..it’s right in front of your face, the whole time it’s been right in front of your face! LOL...I think you misinterpreted/misunderstood something. We're talking about two diff things. He said it AFREZZA. Not "the right instructions, the dosing, the handholding that they need" etc... Anyways, no where did I ever make a comment about any of what you just said! You're lashing out because you're emotionally upset? No you never made that comment, and I didn’t mean to make it sound like you did. You just acted suspicious about the source in another post. And I am annoyed not at you, but that it’s been all this time and this issue has not been addressed to the extent that people would stay on the drug. |
|
|
|
Post by golfeveryday on Feb 26, 2020 18:33:04 GMT -5
Figglebird: Afrezza will never be the stronghold in Type 2. SGLT2i’s and GLP 1’s will rule. Read about Rybellsis the new oral GLP1. Mannkind can’t even get a stronghold with endos for type 1’s. GLP 1’s address the post prandial problem. GLP1’s only work when food hits the intestine (something a certain CEO didn’t know). Of course Afrezza is the greatest way to bring down your PPG, but not at $3000 a month for a type 2. Plus they couldn’t inhale that much inhalable insulin to begin with. If Mannkind doesn’t win the Type 1 war it’s over. And 4 yrs and 4billion dollars later they are not close. Glad to hear we’re still presenting and raising money. Oh..also kids aren’t going to inhale 6-8 times a day for correct coverage. so you just basically said it won’t work for type 2 and kids won’t use it. I hope you are supporting TrepT at Mannkind. |
|
|
|
Post by mango on Feb 26, 2020 18:38:36 GMT -5
Figglebird: Afrezza will never be the stronghold in Type 2. SGLT2i’s and GLP 1’s will rule. Read about Rybellsis the new oral GLP1. Mannkind can’t even get a stronghold with endos for type 1’s. GLP 1’s address the post prandial problem. GLP1’s only work when food hits the intestine (something a certain CEO didn’t know). Of course Afrezza is the greatest way to bring down your PPG, but not at $3000 a month for a type 2. Plus they couldn’t inhale that much inhalable insulin to begin with. If Mannkind doesn’t win the Type 1 war it’s over. And 4 yrs and 4billion dollars later they are not close. Glad to hear we’re still presenting and raising money. Oh..also kids aren’t going to inhale 6-8 times a day for correct coverage. so you just basically said it won’t work for type 2 and kids won’t use it. I hope you are supporting TrepT at Mannkind. is a type 2 and takes Afrezza. I hear he loves it, btw. There's more T2Ds on twitter I follow that use Afrezza and they also love it. So...apparently it works. |
|
|
|
Post by goyocafe on Feb 26, 2020 18:38:48 GMT -5
Figglebird: Afrezza will never be the stronghold in Type 2. SGLT2i’s and GLP 1’s will rule. Read about Rybellsis the new oral GLP1. Mannkind can’t even get a stronghold with endos for type 1’s. GLP 1’s address the post prandial problem. GLP1’s only work when food hits the intestine (something a certain CEO didn’t know). Of course Afrezza is the greatest way to bring down your PPG, but not at $3000 a month for a type 2. Plus they couldn’t inhale that much inhalable insulin to begin with. If Mannkind doesn’t win the Type 1 war it’s over. And 4 yrs and 4billion dollars later they are not close. Glad to hear we’re still presenting and raising money. Oh..also kids aren’t going to inhale 6-8 times a day for correct coverage. so you just basically said it won’t work for type 2 and kids won’t use it. I hope you are supporting TrepT at Mannkind. How did Kendall get pulled into this black hole with such negative sentiment about Afrezza's prospects? Perhaps this is why he has been so quiet. It sounded good on the cover, but the true story was revealed once he got into it for 6 months. |
|
|
|
Post by cjm18 on Feb 26, 2020 18:41:47 GMT -5
Figglebird: Afrezza will never be the stronghold in Type 2. SGLT2i’s and GLP 1’s will rule. Read about Rybellsis the new oral GLP1. Mannkind can’t even get a stronghold with endos for type 1’s. GLP 1’s address the post prandial problem. GLP1’s only work when food hits the intestine (something a certain CEO didn’t know). Of course Afrezza is the greatest way to bring down your PPG, but not at $3000 a month for a type 2. Plus they couldn’t inhale that much inhalable insulin to begin with. If Mannkind doesn’t win the Type 1 war it’s over. And 4 yrs and 4billion dollars later they are not close. Glad to hear we’re still presenting and raising money. Oh..also kids aren’t going to inhale 6-8 times a day for correct coverage. so you just basically said it won’t work for type 2 and kids won’t use it. I hope you are supporting TrepT at Mannkind. Patients are switching to Sglt2 and glp1s from rapid acting insulin? |
|
|
|
Post by mango on Feb 26, 2020 18:55:29 GMT -5
so you just basically said it won’t work for type 2 and kids won’t use it. I hope you are supporting TrepT at Mannkind. How did Kendall get pulled into this black hole with such negative sentiment about Afrezza's prospects? Perhaps this is why he has been so quiet. It sounded good on the cover, but the true story was revealed once he got into it for 6 months. Kendall is constantly traveling and talking to people and constantly stays busy. I know because I emailed someone who is his boss. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 26, 2020 18:55:46 GMT -5
so you just basically said it won’t work for type 2 and kids won’t use it. I hope you are supporting TrepT at Mannkind. is a type 2 and takes Afrezza. I hear he loves it, btw. There's more T2Ds on twitter I follow that use Afrezza and they also love it. So...apparently it works. I don't know where PG is getting his info from but I know at least 5 Type 1's on Afrezza and LOVE IT. I know 2 Pediatric Endos who can't wait to put their patients on it. No one expected Afrezza to be an EARLY SUCCESS when you're going up against the BIG 3 Insulin Makers. I'll tell you one thing....Sanofi (the old CEO) knew the potential of Afrezza. We all know it was going to be a slow climb. Sales are climbing and MNKD is hiring more salespeople. AFREZZA WORKS and people love it. After MNKD gets Pediatric approval and hopefully an improved label.....They will sign a new marketing partner to handle the Type 2 Market. It's not going to happen over night but as long as sales are climbing LIFE IS GOOD. |
|
|
|
Post by sweedee79 on Feb 26, 2020 18:58:02 GMT -5
Pguerro from what I understand either works for mnkd or did.. this is information we at least need to consider..
There are reasons that Afrezza sales have been so low.. it's about time for people to wake up.
I suggest you pay attention to what Sports has been trying so hard to tell us..
I'm not sure I agree with everything that pguerro says as I believe Afrezza is the best for type 1 and 2.. but convincing the market of this at our price point with out the trial data to back it up is another matter. I also believe our CEO has been less than honest about the situation.
|
|
|
|
Post by ktim on Feb 26, 2020 19:02:52 GMT -5
sayhey24 is a type 2 and takes Afrezza. I hear he loves it, btw. There's more T2Ds on twitter I follow that use Afrezza and they also love it. So...apparently it works. I don't know where PG is getting his info from but I know at least 5 Type 1's on Afrezza and LOVE IT. I know 2 Pediatric Endos who can't wait to put their patients on it. No one expected Afrezza to be an EARLY SUCCESS when you're going up against the BIG 3 Insulin Makers. I'll tell you one thing....Sanofi (the old CEO) knew the potential of Afrezza. We all know it was going to be a slow climb. Sales are climbing and MNKD is hiring more salespeople. AFREZZA WORKS and people love it. After MNKD gets Pediatric approval and hopefully an improved label.....They will sign a new marketing partner to handle the Type 2 Market. It's not going to happen over night but as long as sales are climbing LIFE IS GOOD. I certainly thought it would be early success, and I remember many posting here thought that as well. Congrats if you knew it would be so painfully slow. I assume if you bought shares it was at much, much lower price than many of us given your early insight into slow adoption... congrats. Though wish you'd shared that insight. |
|
|
|
Post by sweedee79 on Feb 26, 2020 19:14:44 GMT -5
I was in denial for a long time about Afrezza.. Because I saw what it did for my dad.. But as I found out the market doesn't see what I saw for various complicated reasons.. So I began to realize that I don't know very much about biotech and and how things actually work.. yeah it's unfair and not right.. and I'm pissed.. but I still need to face reality..
We can't market Afrezza in the usual manner.. for one thing we don't have the money.. that is why I think we need Vdex..
|
|
|
|
Post by sayhey24 on Feb 26, 2020 20:03:24 GMT -5
Figglebird: Afrezza will never be the stronghold in Type 2. SGLT2i’s and GLP 1’s will rule. Read about Rybellsis the new oral GLP1. Mannkind can’t even get a stronghold with endos for type 1’s. GLP 1’s address the post prandial problem. GLP1’s only work when food hits the intestine (something a certain CEO didn’t know). Of course Afrezza is the greatest way to bring down your PPG, but not at $3000 a month for a type 2. Plus they couldn’t inhale that much inhalable insulin to begin with. If Mannkind doesn’t win the Type 1 war it’s over. And 4 yrs and 4billion dollars later they are not close. Glad to hear we’re still presenting and raising money. Oh..also kids aren’t going to inhale 6-8 times a day for correct coverage. Figglebird - lets all hope for the sake of all T2s you are wrong. I for one does not want to get gangrene of the balls. I also don't need thyroid cancer. GLP1s are doing a lot more than working when food hits the intestines and I for one don't want any part of them. At the same time having a real fighting chance of stopping the progression and even reversing it is all most T2s would need to know to start using afrezza. But, how many know? Not many I think. I don't know about the $3000 per month, for between $99 and $400 most T2s would do better than using a SGLT2 or GLP1 even if they were under dosing. At $600 few would be underdosing. Where did the $3k come from? No one paying cash is paying that if they are buying from here www.insulinsavings.com/As far as kids inhaling 6 to 8 times per day, it sure beats 6 to 8 shots per day. Heck if they are MDI and lucky they are at 4 shots. Add a few corrections and 6 shots is not that unusual. Will they inhale 6 to 8 times to keep near perfect TIR? I would be shocked if their moms were not at the ready with inhaler at hand. |
|
|
|
Post by sportsrancho on Feb 26, 2020 20:11:23 GMT -5
From Steve....
Stephen Brown
Vice president
Vdex diabetes
Real simple math...
350(avg new patients per week)
X 52 (wks in yr) =18,200 x 4yrs= 72,800 patients. (Approximate)
MNKD says there are 5-6k patients now.
7280 patients would speak to a drop rate of over 90%. Simple
And that is not subtracting those patients that were in the trials and stayed and those from Sanofi.
They can't sell Afrezza because of all the things he/she is saying, which we have all discussed before.
Drs are not putting T2s on insulin or anyone else when they have another choice.
VDEX trains/educates this out of it's providers.
Al made this for Everyone! Especially T2s.
Afrezza works like a dream on all types!!!
VDEX sees T1s/T2s at around the national averages...7% vs 93%.
We get them in control and approved.
Getting a T2 approved for CGM/Afrezza/appointments is always tougher but the results that are possible with Afrezza, really make a huge impact on the argument that one can make to Ins.
Simplified dosing is KEY
Knowing what pitfalls await the patient and a clear and confident way to warn and educate the patient prior is essential.
Knowing what Afrezza is capable of is most important of all.
Without that, they will undervalue and underuse and fail to get the best Afrezza has to offer. "It's ok" "good for corrections"
Rest assured, Afrezza is everything and more that Al said it was.
It's not going anywhere...
It's going everywhere!
SDB
|
|
